

REFERENCES

1. Ludwig J, Viggiano T, McGill D and Oh B. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; **55**: 434-8.
2. Schaffner F and Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; **8**: 283-98.
3. Diehl AM. Non-alcoholic steatohepatitis. Seminars in Liver Disease. 1999; **19**:221-229.
4. Angulo P. Non-alcoholic fatty liver disease. NEJM 2002; **346**:1221-1231.
5. Alba LM et al. Non alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics 2003; **17**:977.
6. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S and Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; **27**: 142-9.
7. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of, and risk factors for, hepatic steatosis in northern Italy. Ann Intern Med 2000; **132**:112-7.

8. Luyckx F, Desai C, Thiry A et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. *Int J Obes Related Metab Disord* 1998; **22**: 222-6.
9. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK and Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. *Am J Gastroenterology* 1999; **94**: 3010-4.
10. Green RM. NASH-hepatic metabolism and not simply the metabolic syndrome. *Hepatology* 2003; **38**: 14-17.
11. Sheth S, Gordon F and Chopar S. Nonalcoholic steatohepatitis. *Ann Intern Med* 1997; **126**: 137-145.
12. Rashid M and Roberts E. Nonalcoholic steatohepatitis in children. *Journal of Pediatrics Gastroenterology Nutrition* 2000; **30**: 48-53.
13. Manton N et al. Non-alcoholic steatohepatitis in children and adolescents. *Med J Aust* 2000; **173**: 476-9.
14. Angulo P, Keach J, Batts K and Lindor K. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; **30**: 1356-62.

15. Itoh S, Yougel T and Kawagoe K. Comparison between non-alcoholic steatohepatitis and alcoholic hepatitis. *Am J Gastroenterology* 1987; **82**: 650-4.
16. Diehl A, Goodman Z and Ishak K. Alcohol-like liver disease in nonalcoholics: a clinical and histologic comparison with alcohol-induced liver disease. *Gastroenterology* 1989; **95**: 1056-62.
17. Pinto H, Baptista A, Camilo M, Valente A, Saragoca A, de Moura MC. Non-alcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. *Dig Dis Sci* 1996; **41**: 172-9.
18. Joseph A, Saverymuttu S, al-Sam S, Cook M and Maxwell J. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radio* 1991; **43**:26-31.
19. Debaere C, Rigauts H and Laukens P. Transient focal fatty liver infiltration mimicking liver metastasis. *J Belge Radiol* 1998; **81**: 174-5.
20. Mitchell D. Focal manifestations of diffuse liver disease at MR imaging. *Radiology* 1992; **185**:1-11.

21. Itoh S, Igarashi M, Tsukada T et al. Non-alcoholic fatty liver with alcoholic hyaline after long term glucocorticoid therapy. *Acta Hepatogastroenterol* 1977; **24**:415-419.
22. Lee R. Non-alcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler. *Hepatology* 1995; **21**:1742-1744.
23. Falchuk K, Fiske S, Hagit R et al. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. *Am J Gastroenterol* 1980; **78**: 535-540.
24. Silverman J, O'Brien K, Long S et al. Liver pathology in morbidly obese patients with and without diabetes. *Am J Gastroenterol* 1990; **85**: 1345-1355.
25. Marchesini G, Brizi M, Morselli-Labate A et al. Association of non-alcoholic fatty liver disease with insulin resistance. *Am J Med* 1999; **107**:450-5.
26. Reynet C and Kahn C. Rad: A member of the Ras family overexpressed in muscle of type II diabetic humans. *Science* 1993; **262**:1441-4.
27. Maddux B, Sbraccia P, Kumakura S et al. Membrane glycoprotein

PC-1 and insulin resistance in non-insulin dependent diabetes mellitus. *Nature* 1995; **373**; 448-51.

28. Cohen B, Novick D and Rubinstein M. Modulation of insulin activities by leptin. *Science* 1996; **274**: 1185-8.
29. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes* 1997; **46**: 3-10. (Erratum, *Diabetes* 1997; 46:536)
30. Hotamisligil G, Peraldi S, Budvari A, Ellis R, White M and Spiegelman B. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF alpha and obesity-induced insulin resistance. *Science* 1996; **271**: 665-8.
31. Fan C, Pan J, Usuda N, Yeldandi A, Rao M and Reddy J. Steatohepatitis, spontaneous peroxisome proliferation and liver tumours in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. *J Biol Chem* 1998; **273**:15639-45.
32. Chavin K, Yang S, Lin H et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J Bio Chem* 1999; **274**: 5692-700.

33. Caldwell S, Swerdlow R, Khan E et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. *J Hepatol* 1999; **31**: 430-4.
34. Sanyal A, Campbell-Sargent C, Mirshani F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001; **120**: 1183-92.
35. Cortez-Pinto H, Chatham J, Chacko V, Arnold C, Rashid A and Diehl A. Alterations in liver ATP homeostasis in human non-alcoholic steatohepatitis: a pilot study. *JAMA* 1999; **282**:1659-64.
36. Day C and James O. Steatohepatitis: a tale of two “hits”? *Gastroenterology* 1998; **114**: 842-5.
37. James O and Day C. Commentary: Non-alcoholic steatohepatitis: another disease of affluence. *The Lancet*. 1999; **353**: 1634-1636.
38. Wanless I and Lentz J. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* 1990; **12**: 1106-10.
39. McNair A. Non-alcoholic steatohepatitis (NASH): why biopsy? *Gut*

- 2002; **51**(6): 898-899.
40. Ratzliff V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in Non-alcoholic fatty liver disease. *Gastroenterology* 2005; **128**(7): 1898-906.
43. Gawrieh S, Rosdo B, Lindor M and Charlton M. Adipokine levels are predictive of histology in patients with non-alcoholic fatty liver disease. *Hepatology*. 2004; **40**: 237A.
44. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H et al. Serum leptin levels in patients with non-alcoholic steatohepatitis. *Am J Gastroenterology* 2000; **95**(12): 3584-9.
45. Vuppalanchi R, Marri S, Kolwankar D, Considine R and Chalasani N. Is adiponectin involved in the pathogenesis of non-alcoholic steatohepatitis? A preliminary human study. *J Clin Gastroenterology* 2005; **39**(3): 237-42.
46. Cope K, Terence R and Diehl AM. Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis. *Gastroenterology* 2000; **119**:1340-1347.
47. Nair S, Cope K, Terence R and Diehl AM. Obesity and female

gender increase breath ethanol concentration: Potential implications for the pathogenesis of non alcoholic steatohepatitis.

Am J Gastroenterol 2001; **96**: 1200-1204.

48. Friedman S. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; **275**: 2247-2250.

49. Bansil R, Stanley P and LaMont J. Mucin biophysics. Annu Rev Physiol 1995; **57**: 635-657.

50. The Merck Manual of Diagnosis and Therapy. Liver disease due to alcohol. 16th Edition; Chap 67: 890-93.

51. Eckel R, Grundy S and Zimmet P. The metabolic syndrome. The Lancet. 2005; **365**: 1415-1428.

52. The metabolic syndrome- a new world-wide definition. The Lancet 2005; **366**: 1059-62.

53. Grundy S et al. Definition of the metabolic syndrome. Circulation. 2004; **109**: 433-438.

54. Grundy et al. Diagnosis and Management of the Metabolic Syndrome. Circulation 2005; **112**: e285-e290.

55. Reaven G. Banting lecture 1988: Role of insulin resistance in

- human disease. Diabetes. 1988; **37**: 1595-1607.
56. Arterburn D and Noel P H. Extracts from “Clinical Evidence”: obesity. BMJ 2000; **322**: 1406-1409.
57. Despres JP, Lemieux I and Prud’homme. Treatment of obesity: Need to focus on high-risk abdominally obese patients. BMJ 2001; **322**: 716-720.
58. Data from South Africa’s first National Demographic and Health Survey, 1998: Guidelines for the prevention and management of overweight and obesity in South Africa. SA Society for the Study of Obesity; Appendix A, Table A1.
59. Ferrannini E, Haffner S, Mitchell B et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991; **34**: 416-422.
60. Abbasi F, Brown B, Lamendola C et al. Relationship between obesity, insulin resistance and coronary heart disease risk. J Am Coll Cardiol. 2002; **40**: 937-943.
61. Ford E, Giles W and Dietz W. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; **287**: 356-

359.

62. Guidelines for Type 2 diabetes at primary care in 2003. Society for Endocrinology, Metabolism and Diabetes of South Africa.
63. Tangerman A. The high sensitive gas chromatographic analysis of ethanol in whole blood, serum, urine and faecal supernatant by the direct injection method. *Clinical Chemistry*. 1997; **43**(6): 1003-1009.
64. Medina J, Fernandez-Salazar L, Garcia-Buey L and Moreno-Otero R. Approach to the pathogenesis and treatment of non-alcoholic steatohepatitis. *Diabetes Care*. 2004; **27**: 2057-2066.
65. Environmental Health Criteria 196: Methanol pp. 1-9 (1997) by The International Programme on Chemical Safety (IPCS) under the joint sponsorship of the UN Environment Programme, the ILO and the WHO.
66. Kugelsmas M et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology* 2003; **38**: 413-419.
67. Ueno T et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol* 1997; **27**: 103-107.

68. Palmer M and Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. *Gastroenterology* 1990; **99**: 1408-1413.
69. Drenick E et al. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. *N Engl J Med* 1970; **282**: 829-834.
70. Neuschwander-Tetri B and Bacon E. Nonalcoholic steatohepatitis. *Med Clin North Am* 1996; **80**: 1147-1166.
71. Sheth S et al. Non-alcoholic steatohepatitis. *Ann Intern Med* 1997; **126**: 137-145.
72. Ludwig J et al. Review: Non-alcoholic steatohepatitis. *J Gastroenterol Hepatol* 1997; **12**: 398-403.
73. Li Z et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. *Hepatology* 2003; **37**: 343-350.
74. Solga S and Diehl. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. *J Hepatol* 2003; **38**: 681-687.
75. Loguercio C et al. Gut-liver axis: a new point of attack to treat

chronic liver damage? Am J Gastroenterol 2002; **97**: 2144-2146.

76. Diagnosis, management and prevention of the common
dyslipidaemias in South Africa. Clinical Guideline 2000. S Afr
Med J 2000; **90**: 164-178.